{"disease":{"id":"active-juvenile-idiopathic-arthritis","name":"Active Juvenile Idiopathic Arthritis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"upadacitinib","indication_name":"Active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"tnf-inhibitor","indication_name":"Active Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":12,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05925452","title":"To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.","phase":"NA","overall_status":"RECRUITING","enrollment_count":221,"lead_sponsor_name":"Changchun GeneScience Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT01844518","title":"Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":219,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT00570661","title":"Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Italfarmaco","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}